Skip to content

Released Dec 14, 2017, after the close

10-Q filed Dec 14, 2017, 75 days after period end · 0001193125-17-369457

Q3 2017 · 10-Q
Revenue$597.00Kno prior Q3 2016 on file+139.8% vs Q2 2017
Net Income-$9.84MN/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$36.02N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$9,966,000N/M
Operating Cash Flowderived-$10,515,000—
Margins · derived
Operating margin-1669.3%
Net margin-1647.6%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2017Q3 2016
Revenue$597.00K—
Net Income-$9.84M-$6.32M
EPS Diluted-$36.02-$23.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR